Advertisement

2014 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Kidney Cancer

Patients With Advanced Papillary Kidney Cancer Respond Well to Bevacizumab/Erlotinib Combination Therapy

Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anticance...

Advertisement

Advertisement



Advertisement

click me